RBC Capital Sticks to Their Buy Rating for Penumbra (PEN)
TipRanksApr 17 03:59 ET
Piper Sandler Remains a Buy on Penumbra (PEN)
TipRanksApr 12 08:29 ET
Penumbra Analyst Ratings
BenzingaApr 3 11:36 ET
Penumbra Analyst Ratings
BenzingaMar 22 09:20 ET
Positive Outlook for Penumbra: Accelerated THUNDER Trial Progress and Thunderbolt System Potential Justify Buy Rating
TipRanksMar 19 06:16 ET
Penumbra's Growth Trajectory and Market Dominance Reinforce Buy Rating
TipRanksMar 4 08:15 ET
Piper Sandler Cuts Inari to Neutral; Cites Slowing Growth, DOJ Probe
Seeking AlphaMar 1 16:03 ET
Analysts Offer Insights on Healthcare Companies: Penumbra (PEN), Jazz Pharmaceuticals (JAZZ) and Argenx Se (ARGX)
TipRanksMar 1 05:04 ET
Piper Sandler Adjusts Price Target on Penumbra to $290 From $310, Maintains Overweight Rating
MT NewswiresFeb 26 11:51 ET
Buy Rating Justified by Penumbra's Market Presence and Projected Growth
TipRanksFeb 25 23:35 ET
Penumbra Analyst Ratings
BenzingaFeb 23 13:34 ET
Deutsche Bank Raises Penumbra Price Target to $288 From $257, Maintains Buy Rating
MT NewswiresFeb 23 10:38 ET
Analysts' Opinions Are Mixed on These Healthcare Stocks: Penumbra (PEN), BioMarin Pharmaceutical (BMRN) and Insulet (PODD)
TipRanksFeb 23 07:51 ET
Maintaining Buy Rating on Penumbra: Strong Growth Prospects and Strategic Focus
TipRanksFeb 23 07:35 ET
Analysts Are Bullish on Top Healthcare Stocks: Collegium Pharmaceutical (COLL), Penumbra (PEN)
TipRanksFeb 23 07:31 ET
Penumbra Analyst Ratings
BenzingaFeb 23 06:15 ET
Analysts Offer Insights on Healthcare Companies: Intra-Cellular Therapies (ITCI), Penumbra (PEN) and BioMarin Pharmaceutical (BMRN)
TipRanksFeb 23 06:10 ET
Hold Rating on Penumbra: Balancing Operational Strengths and Market Expectations
TipRanksFeb 23 05:45 ET
Buy Rating Affirmed: Penumbra's Strong Product Pipeline and Technological Advancements Set to Drive Growth
TipRanksFeb 6 05:37 ET
Truist Financial Remains a Buy on Penumbra (PEN)
TipRanksJan 30 21:25 ET
No Data
No Data